A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study - PubMed (original) (raw)
Clinical Trial
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study
D F Nelson et al. Int J Radiat Oncol Biol Phys. 1986 Oct.
Abstract
This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. One hundred and forty-six evaluable patients were treated with conventional radiation therapy to 60.00 Gy in 6-7 weeks plus BCNU 80 mg/m2/d for 3 days every 8 weeks (XRT + BCNU). One hundred and forty-seven evaluable patients were treated with misonidazole 2.5 gm/m2 once a week for 6 weeks, radiation therapy to 60 Gy and BCNU (MISO + XRT + BCNU). Patients were stratified according to the prognostic factors of age, performance status, and histology. Distribution of these characteristics was comparable among the treatment groups. The median survival for XRT + BCNU was 55.0 weeks, and for MISO + XRT + BCNU 46.0 weeks (p = 0.35). With patients on a minimum dose of dexamethasone of 3 mg/d, misonidazole neurotoxicity included 8.8% peripheral neuropathy, 2.7% CNS toxicity, and a 0.68% ototoxicity. BCNU pulmonary toxicity occurred in 9.3% of patients who received 902-2062 mg/m2 of BCNU.
Similar articles
- A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.
Nelson DF, Schoenfeld D, Weinstein AS, Nelson JS, Wasserman T, Goodman RL, Carabell S. Nelson DF, et al. Int J Radiat Oncol Biol Phys. 1983 Aug;9(8):1143-51. doi: 10.1016/0360-3016(83)90172-4. Int J Radiat Oncol Biol Phys. 1983. PMID: 6347995 Clinical Trial. - Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
Deutsch M, Green SB, Strike TA, Burger PC, Robertson JT, Selker RG, Shapiro WR, Mealey J Jr, Ransohoff J 2nd, Paoletti P, et al. Deutsch M, et al. Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1389-96. doi: 10.1016/0360-3016(89)90939-5. Int J Radiat Oncol Biol Phys. 1989. PMID: 2542193 Clinical Trial. - Is misonidazole neurotoxicity altered by the use of phenytoin and/or dexamethasone in RTOG 79-18 and RTOG 79-16?
Nelson DF, Gillespie BW, Diener MD, Davis DR, Wasserman T, Phillips TL, Stetz J. Nelson DF, et al. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1731-4. doi: 10.1016/0360-3016(84)90538-8. Int J Radiat Oncol Biol Phys. 1984. PMID: 6384162 Clinical Trial. - The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L. Tsao MN, et al. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):47-55. doi: 10.1016/j.ijrobp.2005.05.024. Int J Radiat Oncol Biol Phys. 2005. PMID: 16111571 Review. - Recent and current investigations of radiation therapy of malignant gliomas.
Nelson DF, Urtasun RC, Saunders WM, Gutin PH, Sheline GE. Nelson DF, et al. Semin Oncol. 1986 Mar;13(1):46-55. Semin Oncol. 1986. PMID: 3082011 Review. No abstract available.
Cited by
- Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma.
Li J, Wang M, Won M, Shaw EG, Coughlin C, Curran WJ Jr, Mehta MP. Li J, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):623-30. doi: 10.1016/j.ijrobp.2010.06.012. Epub 2010 Oct 1. Int J Radiat Oncol Biol Phys. 2011. PMID: 20888136 Free PMC article. - Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.
Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Van Meir EG, et al. CA Cancer J Clin. 2010 May-Jun;60(3):166-93. doi: 10.3322/caac.20069. CA Cancer J Clin. 2010. PMID: 20445000 Free PMC article. Review. - Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.
Duntsch C, Divi MK, Jones T, Zhou Q, Krishnamurthy M, Boehm P, Wood G, Sills A, Moore BM 2nd. Duntsch C, et al. J Neurooncol. 2006 Apr;77(2):143-52. doi: 10.1007/s11060-005-9031-y. Epub 2005 Nov 29. J Neurooncol. 2006. PMID: 16314952 - Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment.
Lang O, Liebermeister E, Liesegang J, Sautter-Bihl ML. Lang O, et al. Strahlenther Onkol. 1998 Dec;174(12):629-32. doi: 10.1007/BF03038511. Strahlenther Onkol. 1998. PMID: 9879350 - Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study.
Jeremic B, Shibamoto Y, Grujicic D, Stojanovic M, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J. Jeremic B, et al. J Neurooncol. 2001 Jan;51(2):133-41. doi: 10.1023/a:1010621400203. J Neurooncol. 2001. PMID: 11386410 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical